Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$270.33−0.86 (-0.32%)
Close on Nov 18, 2026Market cap $16.75BP/E 22.2Yield –
Ascendis Pharma A/S gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Ascendis Pharma A/S's gross profit for the twelve months ending Jun 30, 2026 was €955.90M, up 129.5% year over year. For fiscal 2025 it was €625.22M, up 95.8% from the year before. The highest annual figure on record is €625.22M in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €625.22M | +95.8% |
| FY2024 | Dec 31, 2024 | €319.38M | +43.7% |
| FY2023 | Dec 31, 2023 | €222.32M | +469.5% |
| FY2022 | Dec 31, 2022 | €39.04M | +817.4% |
| FY2021 | Dec 31, 2021 | €4.26M | -38.8% |
| FY2020 | Dec 31, 2020 | €6.95M | -48.0% |
| FY2019 | Dec 31, 2019 | €13.38M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €311.63M | +146.2% |
| Q1 FY2026 | Mar 31, 2026 | €229.09M | +174.6% |
| Q4 FY2025 | Dec 31, 2025 | €223.90M | +40.0% |
| Q3 FY2025 | Sep 30, 2025 | €191.28M | +310.2% |
| Q2 FY2025 | Jun 30, 2025 | €126.60M | +416.0% |
| Q1 FY2025 | Mar 31, 2025 | €83.44M | -5.5% |
| Q4 FY2024 | Dec 31, 2024 | €159.89M | +35.2% |
| Q3 FY2024 | Sep 30, 2024 | €46.63M | +14.7% |
| Q2 FY2024 | Jun 30, 2024 | €24.53M | -28.8% |
| Q1 FY2024 | Mar 31, 2024 | €88.33M | +204.9% |
| Q4 FY2023 | Dec 31, 2023 | €118.25M | +564.9% |
| Q3 FY2023 | Sep 30, 2023 | €40.65M | +198.9% |
| Q2 FY2023 | Jun 30, 2023 | €34.46M | +579.2% |
| Q1 FY2023 | Mar 31, 2023 | €28.97M | +1021.9% |
| Q4 FY2022 | Dec 31, 2022 | €17.78M | +1194.3% |
| Q3 FY2022 | Sep 30, 2022 | €13.60M | +1121.7% |
| Q2 FY2022 | Jun 30, 2022 | €5.07M | +396.5% |
| Q1 FY2022 | Mar 31, 2022 | €2.58M | +246.1% |
| Q4 FY2021 | Dec 31, 2021 | €1.37M | – |
| Q3 FY2021 | Sep 30, 2021 | €1.11M | – |
| Q2 FY2021 | Jun 30, 2021 | €1.02M | – |
| Q1 FY2021 | Mar 31, 2021 | €746.00K | – |
See a number that looks wrong?